The Unfulfilled Promise of Inhaled Therapy in Ventilator-Associated Infections: Where Do We Go from Here?

Lucy B. Palmer, MD\textsuperscript{i,}\textsuperscript{*} and Gerald C. Smaldone, MD, PhD\textsuperscript{ii,}\textsuperscript{*}

Abstract

Respiratory infection is common in intubated/tracheotomized patients and systemic antibiotic therapy is often unrewarding. In 1967, the difficulty in treating Gram-negative respiratory infections led to the use of inhaled gentamicin, targeting therapy directly to the lungs. Fifty-three years later, the effects of topical therapy in the intubated patient remain undefined. Clinical failures with intravenous antibiotics persist and instrumented patients are now infected by many more multidrug-resistant Gram-negative species as well as methicillin-resistant \textit{Staphylococcus aureus}. Multiple systematic reviews and meta-analyses suggest that there may be a role for inhaled delivery but “more research is needed.” Yet there is still no Food and Drug Administration (FDA) approved inhaled antibiotic for the treatment of ventilator-associated infection, the hallmark of which is the foreign body in the upper airway. Current pulmonary and infectious disease guidelines suggest using aerosols only in the setting of Gram-negative infections that are resistant to all systemic antibiotics or not to use them at all. Recently two seemingly well-designed large randomized placebo-controlled Phase 2 and Phase 3 clinical trials of adjunctive inhaled therapy for the treatment of ventilator-associated pneumonia failed to show more rapid resolution of pneumonia symptoms or effect on mortality. Despite evolving technology of delivery devices and more detailed understanding of the factors affecting delivery, treatment effects were no better than placebo. What is wrong with our approach to ventilator-associated infection? Is there a message from the large meta-analyses and these two large recent multisite trials? This review will suggest why current therapies are unpredictable and have not fulfilled the promise of better outcomes. Data suggest that future studies of inhaled therapy, in the milieu of worsening bacterial resistance, require new approaches with completely different indications and endpoints to determine whether inhaled therapy indeed has an important role in the treatment of ventilated patients.

Keywords: aerosolized antibiotics, bacterial resistance, ventilator-associated pneumonia

Introduction

Recent systematic reviews of inhaled antibiotics as therapy for ventilator-associated infections (Table 1) demonstrate substantial heterogeneity in terms of indications, endpoints, devices, antimicrobials, and doses of antibiotics.\textsuperscript{(1–4)} Despite this heterogeneity, substantial interest remains in this form of therapy culminating in two large randomized trials of adjunctive inhaled antibiotics.\textsuperscript{(5,6)} Both failed to show more rapid resolution of symptoms or a mortality effect.

Commentaries and editorials discussing these particular trials mentioned possible weaknesses with devices and drug delivery, the choice of the experimental population and endpoints, and they suggested a re-evaluation of the design of future trials.\textsuperscript{(7–11)} The core observations listed in Table 1 suggest that problems in the field are fundamental and indicate a certain irrationality in design and outcomes. Repeated similar studies may not succeed. In this review, we call for a re-exploration of how to treat ventilator-associated infections. Clinical trials should include new treatment algorithms and new endpoints. We address the unique problems of...
Imprecise definitions of the infection being treated\(^{(1)}\)

No consistency in dosing\(^{(1,2,4)}\)

No control of drug delivery devices\(^{(1,4)}\)

Imprecise outcomes such as clinical cure\(^{(2–4)}\)

Unrealistic outcomes such as attributable mortality\(^{(2)}\)

treating respiratory infection in the ventilated patient specifically revisiting airway pathophysiology and the current definitions of respiratory infection in the presence of the endotracheal tube. Contrary to decreasing mortality, or clinical cure of established ventilator-associated pneumonia (VAP), we argue that goals for future investigations should include preventing VAP thus reducing systemic antibiotic use and interrupting the continuing emergence of increasingly resistant pathogens in the ICU.

What Is Respiratory Infection in the Critically Ill Ventilated Patient?

Ventilator-associated infections are fundamentally different than pneumonia in a spontaneously breathing patient. The endotracheal tube causes localized persistent inflammation that favors localized infection and interrupts multiple host defenses such as mucociliary clearance and cough. Like a splinter in the skin, this localized inflammation/infecion will not resolve until the foreign body is removed. Furthermore, all the signs and symptoms associated with pneumonia in the spontaneously breathing patient become nonspecific in the ventilated patient.

Fever, radiographic infiltrates, and increased secretions are common and may not be caused by lung infection. It is not surprising that there is no gold standard for defining ventilator-associated infections. For example, even the seemingly objective measure of quantification of bacterial colony forming units from bronchial lavage fluid (BAL) is highly sensitive and specific only if patients have no prior antibiotic exposure, have been on a ventilator <21 days, and if the BAL followed a standardized technique.\(^{(12–15)}\) These methodological weaknesses were acknowledged in the most recent American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) Guideline from 2016, which did not recommend BAL for the diagnosis of pneumonia.\(^{(16)}\)

Figure 1 describes proposed sequential steps leading to deep lung infection after intubation.\(^{(16–20)}\) After a few days of mechanical ventilation, there is pathogenic colonization of the mouth, aspiration into the airway, followed by bacterial growth that may lead to tracheobronchitis and deep lung infection. Community-acquired pneumonia involves colonization, microaspiration, and/or inhalation but does not involve a foreign body and in most cases cough is intact. The path to ventilator-associated infection differs in multiple significant ways: including the type of organisms that initiate the process, the persistent airway inflammation and epithelial injury from the endotracheal tube, the inability to clear secretions effectively due to loss of cough, impairment of mucociliary clearance, and frequent micro- and macroaspiration.

Figure 2 shows serial clinical data from newly intubated patients qualitatively consistent with the model depicted in Figure 1.\(^{(21,22)}\) As inflammation in the airways progresses, clinical signs emerge such as purulent secretions, low-grade fever, and increasing white blood cell count that all contribute to a clinical picture described by the clinical pulmonary infection score (CPIS).\(^{(22,23)}\) CPIS rapidly rises over time consistent with the chronological progression of infection emanating from the foreign body. Clinicians react to the increasing CPIS (or its components) by starting systemic antibiotics often without a definitive diagnosis. In this context, what treatment plan will be effective? And what are the appropriate outcomes to measure?

What Do the Failures of Systemic Therapy Tell Us?

In a recent systematic review of 27 randomized controlled trials (RCTs) for the treatment of hospital-acquired pneumonia/VAP from 1994 to 2016 by Weiss et al. with systemic therapy, the clinical cure rate was on average 54% with a range of 23%–77%.\(^{(24)}\) Not only is this metric disappointing, but equally disturbing was also the lack of consistency of the definition of “clinical cure.” Definitions varied including “resolution of signs and symptoms” or “improving clinical signs and symptoms” with no additional antibiotic added during the study period, or in some investigations, there was no delineation of what comprised a clinical cure. Assessment of efficacy is difficult to study if investigators are not measuring the same endpoints.

Despite the poor past record, Weiss et al. indicate that the same failings can be found in contemporary studies actively enrolling patients (Clinical Trials.gov).\(^{(24)}\) These have fundamental design problems that may preclude clinical success. For example, many treatment trials use mortality as a primary or secondary endpoint. The recent Phases 2 and 3 trials (IASIS, INHALE), which tested new specially formulated inhaled aerosol formulations, included mortality as a primary endpoint or as part of a hierarchical endpoint.\(^{(5,6)}\)

Mortality is a discrete unarguable endpoint, but it is unlikely to be an achievable endpoint for the treatment of respiratory infection in the critically ill. VAP leads to prolonged intubation and a general increase in resistant organisms but not usually to high attributable rates of death.\(^{(24,25)}\) This failed strategy calls for re-evaluation of why both systemic and adjunctive inhaled therapies have failed to consistently improve outcomes.

Physiological and Microbiological Effects of Inhaled Versus Systemic Therapy

Our current approach to therapy has intrinsic weaknesses. This is well demonstrated by the rapid emergence of resistance that each new antibiotic goes on the market. Increasingly potent systemic antimicrobials soon lose their efficacy as bacteria rapidly mutate and overcome the unique molecular mechanisms that make the antibiotic more active. This is substantiated by the fact that clinical cure rates have not changed and remain ~50%. In fact, FDA approval for new systemic antibiotics is based on noninferiority to older antimicrobials with a similar spectrum of bactericidal activity, suggesting that detecting a superior clinical effect is unlikely.

Pre-clinical pharmacokinetic and pharmacodynamic trials for pneumonia using both systemic and inhaled antibiotics are further complicated by the methods used and accepted...
Adequate drug concentrations are evaluated by the minimum inhibitory concentration (MIC) or area under the curve for the antibiotic and the pathogen under investigation. For pneumonia, drug exposure in the epithelial lining fluid (ELF) is thought by many to be the proper compartment to assess efficacy of drug delivery whether it be systemic or inhaled delivery. For example, the two recently approved systemic antibiotics for ventilator-associated pneumonia, ceftolozane/tazobactam and ceftazidime/avibactam, reported ELF concentrations in support of successful intravenous delivery. Recent trials of inhaled therapy have used ELF concentrations to demonstrate adequate drug delivery as well. However, there are now multiple publications suggesting that ELF concentrations are likely to be inaccurate and result in an overestimation of true parenchymal exposure for inhaled therapy. Furthermore, there are no human studies indicating that ELF concentrations correlate with clinical outcomes. Finally, and perhaps most importantly, concentrations in ELF (an alveolar parameter) do not inform us about a separate compartment of infection, the instrumented...
airway. Here amid viscous and purulent secretions, drug concentrations may need to exceed 10–25 times the MIC of the pathogen to be bactericidal.\(^{36}\)

In the airway, antibiotics may be either inactivated or exhibit reduced effectiveness, secondary to binding to mucin or other airway proteins or to poor penetration into biofilm.\(^{37,38}\) In addition, MICs are a moving target for antimicrobial susceptibility over time. The longer a patient is in the ICU receiving systemic antibiotics for any infection, the more difficult lung infections will be to treat. This clinical effect is secondary to alterations in gut and lung microbiomes with increasing antibiotic resistance.\(^{39–41}\) The presence of these increasingly resistant pathogens led to the trials of adjunctive therapy (inhaled plus systemic). In theory, the combination of both systemic therapy and inhaled therapy should result in high concentrations proximally and distally. Why did this strategy fail?

**Inhaled Delivery of Antibiotics**

**The healthy versus the infected lung**

In experimental animal models of inhaled and intravenous drug delivery, significant differences are found in models that examine healthy lung versus experimental models of pneumonia. Dhanini et al. studied the pharmacokinetics of inhaled and intravenous tobramycin in a healthy lung ovine model of delivery.\(^{49}\) In mechanically ventilated healthy sheep, concentrations of tobramycin were measured in ELF and in the interstitial space fluid after inhaled and intravenous antibiotic administration. This model found higher concentrations of inhaled antibiotics in ELF and interstitial fluid than that achieved by intravenous therapy in these non-infected animals.

This observation did not carry over to infected animals. Two experimental models of inhaled delivery in porcine VAP demonstrated that concentrations of antibiotic were higher in animals with less severe pneumonia.\(^{50,51}\) Goldstein et al. demonstrated that in anesthetized ventilated piglets, tissue concentrations of nebulized amikacin were 3–30-fold greater than those achieved with intravenous therapy.\(^{50}\) However, in areas of severe lower lobe pneumonia, deposition of amikacin was decreased. Ferrari et. al demonstrated similar results in ventilated piglets.\(^{51}\) Subjects with the most severe pneumonia had decreased distal deposition of inhaled ceftazidime.

Most recently, Li Bassi et al. describe an elegant porcine model of severe pneumonia.\(^{52}\) Inhaled amikacin and fosfomycin were compared with IV meropenem alone and combined inhaled and IV therapy. The primary outcome was lung tissue bacterial concentration. Secondary outcomes were tracheal secretions *Pseudomonas aeruginosa* concentration, clinical variables, lung histology, and development of meropenem resistance. Inhaled therapy resulted in more effective bacterial eradication in the tracheal secretions but had negligible effect in lung tissue. Intravenous meropenem was essential for bactericidal activity in the lung parenchyma. Resistance to meropenem increased only in the IV meropenem alone group versus amikacin and fosfomycin + meropenem \(p = 0.004\).

The data are all consistent with our concerns about delivery in well-established infection and may at least partially explain why inhaled therapy lacked robust effects in many trials. It also confirms earlier findings that inhaled therapy protects against resistance caused by systemic antibiotics.

**Review of devices and outcomes in recent trials**

Effective inhaled therapy requires use of a delivery device that is well characterized in terms of its particle size, deposition site, the effect of humidity on its function and the concentrations achieved at the site of infection. It also must be robust and insensitive to ventilator settings, delivering the same reproducible amount with each treatment. Non-nebulizer issues include breath actuation, location of the device in the circuitry, and drug formulation.

This review will not detail the available devices, which are well described elsewhere.\(^{9,53–56}\) However, the application of different devices in recent trials, and effects on clinical and microbiological responses are shown in Table 2.\(^{21,22,42–44,46–48,57–59}\) Even though the type of device used in a trial may directly affect drug efficacy, most published studies using inhaled therapy in the ICU neither describe the method of aerosolization nor the concentration of drug achieved in the lung or secretions. These studies do not meet the basic criteria for acceptable drug delivery.

For all trials given in Table 2, the dose placed in the nebulizer is described but pretrial data on the dose delivered to the lung are only present in a few.\(^{5,6,21,22,30}\) Furthermore, only a few trials examine the eradication of causal bacteria and emergence of resistance.\(^{5,21,22,42}\)

To our knowledge, in most recent trials of inhaled antibiotic therapy to the intubated patient that have failed in clinical response or eradication of causal bacteria, the delivery device was not characterized or often not even mentioned. Although “failure to assess the delivery device” stands out as an important omission in the general literature, this explanation seems inadequate when considering the two recent randomized Phase 2 (IASIS) and Phase 3 trials (INHALE II).\(^{5,6}\) In both, the devices were characterized in advance of the clinical trials in terms of deposition, particle size, and antibiotic concentrations delivered to the airway.\(^{30,60}\)

**IASIS and INHALE Trials**

**Design and outcome of IASIS and INHALE trials**

The Phase 2 RCT (IASIS) conducted by Kollef et al. in 2016 administered a combination of amikacin and fosfomycin through a proprietary drug–device combination to ventilated patients with Gram-negative VAP.\(^{5}\) All patients received IV meropenem or imipenem for Gram-negative coverage for 7 days, and longer if clinically indicated. The endpoints are included in Table 3. No significant differences were found between active drug and placebo in any of the endpoints except in the culture data with a reduction in positive cultures.

The second major trial was INHALE II.\(^{6}\) This was a placebo controlled randomized trial of inhaled amikacin delivered as an adjunct to systemic therapy in mechanically ventilated patients with Gram-negative pneumonia. Both groups received appropriate systemic antibiotics as guided by the 2005 ATS Guidelines for VAP.\(^{61}\) The study failed to reach both primary (survival at days 28–32) and secondary outcome measures (Table 4).
| Authors                  | Year | Setting         | Design                          | Indication                                                                 | Drug and Method of Aerosolization: No. of Patients on IA or IV or Placebo | Organisms in Patients                                                                 | Number of Patients with Eradication of Causative Organism | Number of Patients with Newly Resistant Organisms | Clinical Response                                                                 | Adverse Events                  |
|-------------------------|------|-----------------|---------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------|---------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|
| Palmer et al. (21)      | 2008 | ICU, United States | Randomized double-blind placebo controlled | VAT ≥2mL sputum/4 hours and organism on Gram stain | Vancomycin and/or gentamicin jet nebulizer; placebo-24; 19/24 IA-19; 17/19 (89%) also received IV | Multiple species of Gram-negative and Gram-positive organisms IA 12/12 (100%) isolates at day 14 Placebo; 5/19 (26%) isolates at day 14 | IA 8/24 (33%); IA 0/19 (0%) | | Resolution of VAP (adjusted OR, -0.29; 95% CI, 0.13–0.66, p = 0.006) Reduced use of systemic antibiotic p = 0.042 Increased weaning p = 0.046 | No bronchial constriction |
| Kofteridis et al. (42)  | 2010 | ICU, Greece     | Retrospective review, matched case control | VAP Clinical diagnosis + endotracheal secretions or BAL | Colistin; Aerosolization— not described IV and aerosolized colistin—43 IV colistin—43 | Acinetobacter 66 Klebsiella 12 Pseudomonas 8 All susceptible to colistin | IV = 17/34 (50%); IV+IA, 19/42 (45%) p = 0.679 | | No resistance in IA group; Resistance in IV group not described | Renal impairment no different in either group No neurotoxicity in either group No bronchial constriction |
| Korbila et al. (43)     | 2010 | ICU, Greece     | Retrospective review, matched case control | VAP Clinical diagnosis and quantitative cultures of respiratory specimens | Colistin Aerosolized through Siemens Servo ventilator, aerosolized colistin+IV-78 IV colistin—43 | MDR Gram-negative organisms; A. baumanii, Pseudomonas aeruginosa, Klebsiella spp.; All colistin susceptible | Not described | | | | |
| Rattanaumpawan et al. (44) | 2010 | ICU, Thailand   | Open label RCT                  | VAP Clinical diagnosis plus Gram negative in secretions | Colistin Aerosolization— not described IA+IV-51 Placebo+IV—49 | Colistin susceptible P. aeruginosa and A. baumanii | IA+IV 31/51 (61%); Placebo + IV 19/49 (39%), p = 0.03 | | | No difference in renal impairment or bronchial constriction | |
| Lu et al. (46)           | 2011 | ICU, France     | Randomized trial comparing IA with IV antibiotics | VAP Clinical diagnosis + BAL or mini-BAL | Vibrating plate nebulizer Nebulized amikacin and ceftazidime n= 20 amikacin and ceftazidime IV n=20 | P. aeruginosa susceptible to drugs IA - 16/16 (100%) on day 5; IV-7/15 (47%) on day 5 | IA day 9, 0/12 (0%); IV day 9, 5/11 (45%) | | IA-Hypoxemia-3/20 (15%) Expiratory filter occluded-3/20 (15%) 1/20 (5%) cardiac arrest | (continued) |
| Authors          | Year | Setting                      | Design                                      | Drug and Method of Aerosolization: No. of Patients on IA or IV or Placebo | Number of Patients with Eradication of Causative Organism | Number of Patients with Newly Resistant Organisms | Clinical Response | Adverse Events |
|------------------|------|------------------------------|---------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------|-------------------|---------------|
| Arnold et al. (47) | 2012 | MICU United States           | Retrospective chart review with cohort study | VAP Clinical diagnosis + BAL | P. aeruginosa and Acinetobacter baumannii susceptible to drug administered | Not described | Not described | Increased survival by Kaplan-Meier for IA+IV $p=0.030$ | IA+IV 1 episode of bronchial constriction; 1 episode of renal impairment |
| Lu et al. (48)   | 2012 | ICU, France                  | Prospective observational comparator        | VAP Clinical dx + BAL or blind mini-BAL | P. aeruginosa and Acinetobacter spp, $\beta$-lactam susceptible | Not described | Reported for patients with recurrent infection IA 4/16 (25%) converted from $\beta$-lactam resistant to susceptible after inhaled therapy IV 24/32 = 75% of isolates developed new resistance 6/32 became resistant to all $\beta$-lactams | Clinical cure; $\beta$-lactam sensitive 81/122 (66%); $\beta$-lactam resistant 29/43 (67%) $p=NS$; Mortality; $\beta$-lactam sensitive 28/122 (7%); $\beta$-lactam resistant on IA 7/43 (16%) $p=0.357$ | No renal toxicity observed in both groups |
| Niederman et al. (57) | 2012 | Multisite Phase 2 trial in United States Spain and France | VAP-clinical diagnosis Proprietary amikacin BAY41-6551 vibrating mesh nebulizer | VAP Clinical diagnosis + BAL or tracheal aspirates | Gram-negative organisms Predominant species—*Pseudomonas* Inhaled amikacin $^a$ 22/33 (68.8%) Placebo 10/16 (62.5%) | Not described | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h | Inhaled amikacin $^a$ Q 12, 93.8% (15/16), Inhaled amikacin $^b$ Q 24H 75.0% (12/16), and Placebo 87.5% (14/16) ($p=0.467$) mean number of antibiotics per patient per day Inhaled amikacin $^b$ Q12 0.9/day in the q12h |

(continued)
| Authors                  | Year | Setting       | Design                                                                 | Indication                                                                 | Drug and Method of Aerosolization: No. of Patients on IA or IV or Placebo | Organisms in Patients | Number of Patients with Eradication of Causative Organism | Number of Patients with Newly Resistant Organisms | Clinical Response | Adverse Events |
|-------------------------|------|---------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------|----------------------------------------------------------|------------------------------------------------|-------------------|----------------|
| Doshi et al. (58)       | 2013 | Medical Surgical ICUs, United States | Retrospective multi-center cohort study | VAP diagnosed by BAL or endotracheal secretions | Colistin Aerosolized with jet nebulizers or vibrating mesh nebulizer; IV only = 51 patients IV plus IA colistin = 44 | IV patients: *Acinetobacter* 25/51 (49%); *Pseudomonas* 35/51 (69%); ESBL 9/51 (18%); IV+IA *Acinetobacter* 36/44 (82%); *Pseudomonas* 18/44 (41%); ESBL 2/44 (5%) All organisms susceptible to colistin | IV 27/51 (53%); IV+IA 18/44 (41%); p = 0.805 | Not described | In patients diagnosed with BAL, IV-9/32 (31.3%); IV + 1A 19/35 (57%); p = 0.033 |
| Tumbarello et al. (59)  | 2013 | ICU, Italy | Retrospective cohort study | VAP diagnosed by BAL with organisms with COS | Colistin Jet or ultrasonic nebulizers; IV = 104 IV + IA-104 | IV *Acinetobacter* 72/104 (69%); *Pseudomonas* 24/104 (23%); *Klebsiella* 8/104 (8%); IV plus IA *Acinetobacter* 56/104 (54%); *Pseudomonas* 28/104 (27%); *Klebsiella* 20/104 (19%) All organisms were COS | IV 52/84 (62%); IV+IA 42/82 (51%); p = 0.08 | Not reported | IV 57/104 (55%); IV+1A 72/104 (69%); p = 0.03 |
| Palmer and Smaldone (22) | 2014 | MICU SICU, United States | Randomized double-blind placebo controlled | VAT ≥2 mL sputum/4 hours and organism on Gram stain | Jet nebulizer Placebo plus IV n = 18 Inhaled antibiotic plus IV n = 24 Inhaled antibiotics included | Predominantly MDRO including MRSA and Gram-negative MDRO | IA+IV 26/27 (96%) isolates Placebo + IV 22/23 (9%) isolates | IA+IV 0/7 (0%) of new resistance to aerosolized drug, 2/16 (13%) new MDRO IA + IV vs. Placebo + IV CPIS deceased significantly only in IA, p = 0.0008 | Creatinine similar in both groups at end of trial, no renal toxicity | (continued) |
| Authors | Year       | Setting                                            | Design                                      | Drug and Method of Aerosolization: No. of Patients on IA or IV or Placebo | Organisms in Patients                                              | Number of Patients with Eradication of Causative Organism | Number of Patients with Newly Resistant Organisms | Clinical Response | Adverse Events |
|---------|------------|----------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------|-------------------|----------------|
| Kollef et al.\(^{(5)}\) | 2016 | ICUs in Europe, Middle East, and United States | Randomized double-blind placebo controlled | VAP with clinical diagnosis and Gram-negative organisms in BAL or mini BAL | Gram-negative organisms | IA and IV = 1/12, Placebo plus IV 8/29 | Placebo + IV 6/11 (56%) new resistance | No difference in CPIS between groups | No increase in renal toxicity in the IA plus IV group vs. placebo and IV |
| Hassan et al.\(^{(45)}\) | 2018 | CT ICU Cairo | Randomized Aerosol vs. IV amikacin as adjunctive therapy with systemic therapy | Pneumatic nebulizer for intubated patients | MDR Gram-negative organisms | 16/47 | NA | Inhaled 79/86 IV amikacin 33/47 \(p = 0.002\) | Decline in creatinine clearance Inhaled amikacin 12/86 Adjunctive IV amikacin 16/47 \(p = 0.001\) |
| Niederman\(^{(11)}\) | 2019 | Multisite ICUs, 25 countries | Randomized double-blind placebo controlled | VAP with Gram-negative organisms | Gram-negative organisms | Not described | IA + IV: P. aeruginosa 68/75 (73%); A. baumannii 46/77 (60%); Placebo + IV: P. aeruginosa 43/88 (50%); A. baumannii 43/69 (62%) | IA + IV: Placebo + IV: 149 (58%) \(p = 0.43\) | Device-related ventilator circuit occlusion 2/712 Cardiac arrest 2/712 |

Note: Only the two most common Gram-negative organisms are shown.

Modification of Table from Palmer LB: Aerosolized antibiotics for ventilator-associated infections. Chapter 10.4. In: Dhand R, editor. Textbook of Aerosol Medicine. Knoxville (TN): International Society of Aerosols in Medicine; 2015. p.e1–28. Available from: www.isam.org

\(^{a}\)A proprietary amikacin BAY41-6551 (NCT01004445).

AFIS, amikacin and fosfomycin inhalation system; COS, colistin only susceptible; CPIS, clinical pulmonary infection score; HAP, hospital-acquired pneumonia; IA, inhaled antibiotic; ICU, intensive care unit; IV, intravenous; MDR, multidrug resistant; MDRO, multidrug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; RCT, randomized controlled trial; VAP, ventilator associated pneumonia; VAT, ventilator associated tracheobronchitis.
Examination of the bacterial eradication effects of the two trials suggests that there may have been problems with delivery of bactericidal concentrations. For example, Table 3 indicates that 17% of IASIS patients were still infected at day 7. The results from INHALE are given in Table 4. In that study, the four most common pathogens were *Acinetobacter baumanii*, *Eschericia coli*, *Klebsiella pneumonia*, and *P. aeruginosa*. Eradication was higher in the active arm for all but *A. baumanii*. However, the eradication rate for these four pathogens was never >75%. This result also implies that, in the clinical arena the delivery device may not have reliably delivered adequate doses to all areas of infection, although the reported concentrations in the tracheal aspirates were also many times the MIC of the organisms.

This assessment is supported by observations from other clinical studies wherein the investigators rigidly controlled device and delivery conditions during their trials.(21,22) Palmer and colleagues in two placebo controlled trials used a tightly controlled form of jet nebulizer delivery in patients with VAT or VAT with VAP that resulted in both clinical and bacteriological success, including complete eradication of pathogens in tracheal aspirates at end of treatment. Furthermore, in patients with follow-up cultures, from 1 to 3 days post-treatment, the eradication rate for *A. baumanii* was >95%.

### Table 3. IASIS Endpoints for Active Drug (n=71) and Placebo (n=71)

| Primary end point | p |
|-------------------|---|
| CPIS baseline (mean ± SD) | 5.6 ± 1.5 | 5.5 ± 1.6 | NS<sup>a</sup> |
| CPIS day 10 (mean ± SD) | 5.0 ± 3.1 | 4.8 ± 3.4 | 0.81 |

Secondary hierarchal composite endpoint of mortality and time to clinical cure (no. of patients)

| p |
|---|
| Mortality first | 10 | 10 | 0.68 |
| Clinical cure | 15 | 18 | 0.81 |

Secondary hierarchal composite endpoint of mortality and ventilator-free days (no. of patients)

| p |
|---|
| Mortality first | 10 | 10 | 0.06 |
| Ventilator-free days | 13 | 27 | 0.06 |

| Positive cultures | p |
|-------------------|---|
| Tracheal cultures at day 1: Positive for Gram-negative organisms | 19 (27) | 40 (56) | 0.001 |
| Tracheal cultures at day 7: Positive for Gram-negative organisms | 12 (17) | 29 (41) | 0.002 |

The reported tracheal aspirate concentrations for amikacin and fosfomycin, respectively, were 7720 µg/mL and 2430 µg/mL on day 3 and 7782 µg/mL and 2685 µg/mL, respectively, on day 10.

<sup>a</sup>Actual p value not in publication.

### Table 4. Summary of INHALE Endpoints

| Primary endpoint | p<sup>a</sup> |
|------------------|---|
| Survival at days 28–32 | 191 (75%) | 196 (77%) | 0.43 |

Secondary hierarchal composite endpoint

| Early clinical response<sup>b</sup> | 149 (58%) | 145 (57%) |

| Secondary endpoints | p |
|---------------------|---|
| Attributable mortality | 43 (67%) | 36 (63%) |
| Days on ventilator, mean (SD) | 20.6 ± 10.1 | 20.2 ± 10.2 |

| Microbiological endpoints % (range) |
|-------------------------------------|
| Eradication at test of cure (days 17–19) | 71% (60–80) | 68.5 (50–100) |
| Emergence of new pathogens | 21 (8.2%) | 34 (13.5) |

<sup>a</sup>Active drug n = 255 Placebo (n = 253).<sup>4,24</sup> <sup>b</sup>p values only calculated for survival. 

Despite high concentrations of antibiotic, Table 3 indicates that 17% of IASIS patients were still infected at day 7. The results from INHALE are given in Table 4. In that study, the four most common pathogens were *Acinetobacter baumanii*, *Eschericia coli*, *Klebsiella pneumonia*, and *P. aeruginosa*. Eradication was higher in the active arm for all but *A. baumanii*. However, the eradication rate for these four pathogens was never >75%. This result also implies that, in the clinical arena the delivery device may not have reliably delivered adequate doses to all areas of infection, although the reported concentrations in the tracheal aspirates were also many times the MIC of the organisms.

This assessment is supported by observations from other clinical studies wherein the investigators rigidly controlled device and delivery conditions during their trials.(21,22) Palmer and colleagues in two placebo controlled trials used a tightly controlled form of jet nebulizer delivery in patients with VAT or VAT with VAP that resulted in both clinical and bacteriological success, including complete eradication of pathogens in tracheal aspirates at end of treatment. Furthermore, in patients with follow-up cultures, from 1 to 3 days post-treatment, the eradication rate for *A. baumanii* was >95%.

### Table 5. Future Outcomes for Inhaled Antibiotics That Prevent Ventilator-Associated Pneumonia and Its Sequelae

- Decreased need for initiation of systemic antibiotics for respiratory infection during the trial
- Decreased emergence of resistance post-treatment both in the respiratory sites and nonrespiratory sites
- Decreased daily dose of systemic antibiotics in the ICU
- Increased ventilator free time
- Decreased antibiotic related diarrhea and specifically *Clostridium difficile* colitis
4 weeks post-treatment, there was still no growth. They also found that inhaled therapy prevented the progression from VAT to VAP.

**Designing Clinical Trials for Ventilator-Associated-Infection**

*Current trial designs may be cause of failure*

In VAP trials, the patient populations usually have well-established pneumonia. The severity of illness, prior exposure to antibiotics, and the length of time on ventilation may have contributed to the treatment failure in the IASIS and INHALE 2 trials.\(^{(5,6)}\) In the IASIS trial, the authors themselves indicated that failure to show a treatment difference between arms might have been secondary to late initiation of aerosol therapy. Many of their patients had received up to 6.6 days of intravenous therapy (for non-respiratory sites) before initiation of inhaled therapy.

Supporting this theory, they also noted that the United States component of the study had more robust changes in CPIS and these patients had received only 3 days of IV antibiotics before inhaled therapy. However, this improvement was not associated with better clinical cure or secondary hierarchical mortality effect. Furthermore, in subgroup analysis of randomized patients in the ICU for <5 days and receiving <2 days of prior IV antibiotic, there was a much more robust change in CPIS in both arms (3 points lower in active arm and 2.5 points lower in placebo), suggesting that earlier treatment may have led to more robust results.

In the INHALE trial, analysis of the clinical data indicates that their patients also had advanced disease.\(^{(6)}\) In the intention to treat population, 167 of 354 of the active arm patients and 172 of 358 of placebo patients had Apache scores >20. Furthermore, pneumonia-attributable mortality was unusually high. For patients who received active drug, the pneumonia-attributable mortality was 67.2%, and in the placebo group, mortality was 63.2%. Most other studies report mortality rates of only 9%–13%.\(^{(25,62,63)}\) These differences suggest unusual severity of pneumonias in the INHALE population of patients. A mortality endpoint in the ICU is a high bar for any form of therapy.

The severity of illness in these ventilator-related infections, the antibiotic therapy given before enrollment in some cases, the failure of the inhaled treatment to eradicate organisms, and the insensitivity of mortality to different antibiotic therapies forecast the failure of these trials.

**IASIS and INHALE devices**

Therapeutic trials of antibiotics require reasonable control of the delivered dose. This can be difficult in the intubated patient.\(^{(64)}\) Two major factors that might interfere with drug delivery are the device itself or the influence of the ventilator.

Both INHALE and IASIS used vibrating mesh nebulizers. Mesh devices are electronic and unlike jet nebulizers do not require added flow to the ventilator circuit. The devices used were proprietary, and detailed studies documenting drug delivery with repeated use are not available. The INHALE trial used Aerogen technology, the pulmonary drug delivery system (PDDS), which was breath actuated.\(^{(66)}\) In recent studies of the Aerogen Solo, a device similar to that used in the INHALE study but not breath actuated, a random failure rate of 30% was found in 40 experimental runs testing these devices on the bench.\(^{(65)}\)

Additional studies during mechanical ventilation reported high residual nebulizer volumes or not nebulizing at all. Failure of gravitational feed was noted as well as bubble formation on the mesh particularly when used during mechanical ventilation.\(^{(66,67)}\) In the IASIS trial, an inline vibrating plate electronic nebulizer (eFlow Inline System; PARI GmbH) was used.\(^{(5)}\) Rottier et al. tested PARI eFlow devices and found >50% of the time the eflow switched off after 19 minutes.\(^{(68)}\)

Ventilator effects are complex and will not be reviewed here in detail. The major factor affecting delivery is the duty cycle, the fraction of the breath taken up by inspiration. Breath actuation minimizes duty cycle effects. In INHALE, the PDDS was breath actuated, but in IASIS, the eflow was not. In IASIS, changes in ventilator settings may have affected drug delivery.

Although data from INHALE and IASIS are limited, tracheal antibiotic concentrations reported in INHALE were very variable ranging from 2890 to 41,602 mg/L. Such variability suggests inconsistent delivery.\(^{(6)}\) Better control of antibiotic levels has been reported with alternative breath-actuated delivery systems. Using a jet nebulizer, Miller et al. found that variability in antibiotic concentration in tracheal secretions could be tightly controlled with breath actuation and humidifier bypass.\(^{(69)}\)

**Inhaled therapy: effects on bacterial resistance**

An important metric in all future trials of inhaled antibiotics is the emergence of new resistance to the drug administered. Although systemic therapy is the only recommended treatment for ventilator-associated infection, there is a direct relationship with the amount of systemic antibiotics prescribed and the emergence of increased resistance. This fact, compounded with relatively poor cure rates, is the situation we are currently forced to accept.

If inhaled antibiotics could reduce the use of systemic antibiotics for respiratory infections, which are responsible for >50% of antibiotic use in the ICU, their use could reverse the increase in resistance seen today.

A common misconception is that aerosolized antibiotics increase bacterial resistance. Table 2 shows data from modern studies that were markedly different in design from the distant trials of the 70s that gave inhaled therapy a bad reputation.\(^{(70)}\) Between 2008 and 2017, five RCTs and one case-control study analyzed post-treatment cultures and found no increase in resistance in patients treated with aerosol therapy.\(^{(5,21,22,32,46,48)}\) Our group, using a well-characterized and robust aerosol delivery system, changed the spectrum of resistance in the intensive care unit.\(^{(22)}\) In our trials, inhaled antibiotics eradicated all pathogens including multiple drug-resistant organisms.\(^{(21,22)}\)

All patients who acquired resistant organisms post-treatment received only systemic antibiotics. Similarly, Lu et al.’s randomized trial of intravenous versus inhaled antibiotics (as exclusive treatment) also showed the emergence of resistance only in the comparator group that received systemic antibiotics.\(^{(46)}\) Finally, in the IASIS trial, cultures that remained positive (12 of 71 active drug patients and 29 of 71 patients in the placebo group) were studied for the emergence of resistance.
The MICs of these cultures were compared with the MIC at the time of randomization. Of these cultures, 1 of 12 in the active drug group and 8 of 29 in the placebo group had a fourfold increase in MIC during the trial. The emergence of resistance to amikacin in the INHALE study in patients receiving inhaled active drug is of great interest, but those data have not been published.

Future therapy

As we have already outlined, it is our opinion that studies to date may have failed because of either device technology or protocol design. The indications for treatment and the endpoints should be reconsidered in view of the data already summarized. Treating with adjunctive therapy for VAP (the approach used for both INHALE and IASIS) may be too late in the course of infection. Therefore, what is the optimal time to begin therapy?

Can we treat early tracheobronchitis and avoid well-developed VAP? Will inhaled therapy mitigate the need for systemic antibiotics and reduce resistance? Placebo-controlled trials designed to treat tracheobronchitis in patients identified as high risk for VAP, if successful, could answer these questions. The model in Figure 1 predicts localized inflammation and infection after a few days of intubation. What evidence supports earlier treatment?

Falagas et al., in a meta-analysis, reviewed the literature from 1950 to 2005. Of the 12 trials that could be considered prophylactic for VAP, there were 8 investigations that were either RCTs or prospective comparative trials. Aerosolized gentamicin was used in three trials, polymyxin in two trials, tobramycin in one trial, and ceftazidime in one trial. There were 1877 patients included in the meta-analysis. Primary outcomes included incidence of VAP and mortality.

An important secondary outcome was colonization with P. aeruginosa. Analysis of five RCTs demonstrated a reduction in VAP in the treated patients with an odds ratio (OR) of 0.49 (95% CI 0.32–0.76). Falagas and colleagues also included two nonrandomized trials, which yielded similar results for VAP. The latter studies were of added interest because there was a reduction in VAP in patients colonized with P. aeruginosa (OR, 0.51; 95% CI 0.30–0.86). A more recent systematic review and meta-analysis in 2018 by Pvoa et al. demonstrated that prophylactic antibiotics administered through the respiratory tract reduced the occurrence of VAP when compared with placebo or no treatment (OR 0.53; 95% CI 0.34–0.84).

This effect was seen only when antibiotics were given by nebulization (OR 0.46; 95% CI 0.22–0.97), but not when they were administered by intratracheal instillation (OR 0.57; 95% CI 0.28–1.15). Although suggestive, none of these studies were designed to lead to formal approval of inhaled therapy, so universal availability of these protocols would be difficult to implement.

Putting all these analyses together, early treatment of tracheobronchitis targeted to the airways seems to have most potential for success. A modern early treatment trial would require a device designed to work with all commonly used ventilators with reproducible dosing in most settings. This is a high bar because ventilator circuits/humidifiers are not standardized and there is an interaction between aerosol delivery systems and the ventilator circuit that is difficult to control. However, the combination of consistent dosing in all patients and early treatment may be the best approach to preventing pneumonia with the added benefits of reducing the use of systemic antibiotics and bacterial resistance in critically ill patients. Potential benefits are listed in Table 5.

Conclusion

We believe that the way forward is early intervention in airway infection. We have emphasized (1) early treatment is given before highly resistant organisms are present, as opposed to after they are present, (2) early treatment reduces the chance of bacterial resistance, (3) delivery is more effective at proximal sites of infection, (4) early topical therapy may avoid the use of systemic therapy, and (5) clinical trial design is facilitated because early treatment uses the development of pneumonia as an endpoint rather than mortality, which is likely unattainable in any ICU study of antibiotics.

Authors’ Contributions

L.B.P. reviewed the literature. L.B.P. and G.C.S. contributed to the conception of the review, the writing, and the editorial changes. Both authors accepted the final draft of the article.

Acknowledgment

Many thanks to Lorraine Morra who provided technical support for figures, tables, and formatting of the article.

Author Disclosure Statement

The State University of New York owns patents on the delivery of inhaled antibiotics to intubated patients licensed to InspiRx, Inc. This portfolio includes new devices designed to treat patients maintained on mechanical ventilation. G.C.S. serves as a consultant to InspiRx and is a member of the advisory board.

Funding Information

No funding was received for this article.

References

1. Zampieri FG, Nassar AP, Jr., Gusmao-Flores D, Taniguchi LU, Torres A, and Ranzani OT: Nebulized antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis. Crit Care. 2015;19:150.
2. Valachis A, Samonis G, and Kofiteridis DP: The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: A systematic review and meta-analysis. Crit Care Med. 2015;43:527–533.
3. Russell CJ, Shiroishi MS, Siantz E, Wu BW, and Patino CM: The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: A systematic review. BMC Pulm Med. 2016;16:40.
4. Xu F, He LL, Che LQ, Li W, Ying SM, Chen ZH, and Shen HH: Aerosolized antibiotics for ventilator-associated pneumonia: A pairwise and Bayesian network meta-analysis. Crit Care. 2018;22:301.
5. Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, Janos G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, and...
Montgomery AB: A randomized trial of the amikacin fosfonycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest. 2017;151:1239–1246.
6. Niederman MS, Alder J, Basseti M, Boateng F, Cao B, Corkery K, Dhand R, Kaye KS, Lawatscheck R, McLereth P, Nicolau DP, Wang C, Wood GC, Wunderink RG, and Chastre J: Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALAE): A double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2020;20:330–340.
7. Shorr AF, and Zilberberg MD: The answer for inhaled antibiotics in pneumonia is still blowing in the wind. Chest. 2017;151:1201–1203.
8. Sweeney DA, and Kalil AC: Didn’t inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumonia. Crit Care. 2018;22:333.
9. Torres A, Motos A, Battaglini D, and Li Bassi G: Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: Current status and future prospects. Crit Care. 2018;22:343.
10. Ehrmann S, Chastre J, Diot P, and Lu Q: Nebulized antibiotics in mechanically ventilated patients: A challenge for translational research from technology to clinical care. Ann Intensive Care. 2017;7:78.
11. Niederman MS: Adjunctive nebulized antibiotics: What is their place in ICU infections? Front Med (Lausanne). 2019;6:99.
12. Meduri GU, and Chastre J: The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest. 1992;102:557S–564S.
13. Kollef MH, and Ward S: The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412–420.
14. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, and Tenaillon A: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132:621–630.
15. Baram D, Hulse G, and Palmer LB: Stable patients receiving prolonged mechanical ventilation have a high alveolar burden of bacteria. Chest. 2005;127:1353–1357.
16. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Curratala J, El Solh AA, Ewig S, Fey PD, File TM, Jr., Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, and Brozek JL: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.
17. Durairaj L, Mohamad Z, Launsbach JL, Ashare A, Choi JY, Rajagopal S, Doern GV, and Zabner J: Patterns and density of early tracheal colonization in intensive care unit patients. J Crit Care. 2009;24:114–121.
18. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, Menendez R, and Bonastre J: Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: A state of concept. Crit Care. 2012;16:R93.
19. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH, and Group VAPOSA: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122:2115–2121.
20. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, and Brun-Buisson C: Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998;129:433–440.
21. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O’Riordan T, Daroowalla F, and Richman P: Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008;36:2008–2013.
22. Palmer LB, and Smaldone GC: Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014;189:1225–1233.
23. Singh N, Rogers P, Atwood CW, Wagener MM, and Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Resp Crit Care Med. 2000;162:505–511.
24. Weiss E, Essaied W, Adrie C, Zahar JR, and Timsit JF: Treatment of severe hospital-acquired and ventilator-associated pneumonia: A systematic review of inclusion and judgment criteria used in randomized controlled trials. Crit Care. 2017;21:162.
25. Melsen WG, Rovers MM, Koeman M, and Bonten MJ: Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med. 2011;39:2736–2742.
26. Dimelow R, Wright JG, MacPherson M, Newell P, and Das S: Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers. Drugs R D. 2018;18:221–230.
27. Xiao AJ, Miller BW, Huntington JA, and Nicolau DP: Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
28. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, and Baltopoulos GJ: Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38:1779–1786.
29. Boisson M, Jacobs M, Gregoire N, Gobin P, Marchand S, Couet W, and Minoz O: Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58:7331–7339.
30. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy VL, Wood C, Corkery K, Gribben D, and Chastre J: Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care Med. 2014;42:224–230.
31. Kiem S, and Schentag JJ: Interpretation of antibiotic concentrations. Anesthesiology. 2019;33:311–318.
32. Kiem S, and Schentag JJ: Interpretation of epithelial lining fluid concentrations overestimate lung tissue concentrations. Anesthesiology. 2019;131:229–232.
34. Rodvold KA, Yoo L, and George JM: Penetration of anti-
infecive agents into pulmonary epithelial lining fluid:
Focus on antifungal, antitubercular and miscellaneous anti-
fective agents. Clin Pharmacokinet. 2011;50:689–704.
35. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr.,
Craig W, Billette M, and Dolaviso JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: A
consensus review of the American Society of Health-
System Pharmacists, the Infectious Diseases Society of
America, and the Society of Infectious Diseases Pharma-
cists. Am J Health-Syst Pharm. 2009;66:82–98.
36. Mendelmann PM, Smith AL, Levy J, Weber A, Ramsey B,
and Davis RL: Aminoglycoside penetration, inactivation,
effacy in cystic fibrosis sputum. Am Rev Respir Dis.
1985;132:761–765.
37. Stewart PS, and Costerton JW: Antibiotic resistance of
bacteria in biofilms. Lancet. 2001;358:135–138.
38. Huang JX, Blaskovich MA, Pelingon R, Ramu S,
Kavanagh A, Elliott AG, Butler MS, Montgomery AB, and
Cooper MA: Mucin binding reduces colistin antimicrobial
activity. Antimicrob Agents Chemother. 2015;59:5925–5931.
39. Wolff NS, Hugenhoft F, and Wiersinga WJ: The emerging
role of the microbiota in the ICU. Crit Care. 2018;22:78.
40. Ruppe E, Lisboa T, and Barbier F: The gut microbiota of
critically ill patients: First steps in an unexplored world.
Intensive Care Med. 2018;44:1561–1564.
41. Dickson RP, Singer BH, Newstead MW, Falkowski NR,
PROMISE OF INHALED ANTIBIOTICS 23
344–355.
42. Doshi NM, Cook CH, Mount KL, Stawicki SP, Frazier EE,
Personett HA, Schramm GE, Arnold HM, and Murphy CV:
Adjuvant aerosolized colistin for multi-drug resistant
gram-negative pneumonia in the critically ill: A retro-
spective study. BMC Anesthesiol. 2013;13:45.
43. Tumbarello M, De Pascale G, Trecarichi EM, De Martino
S, Bello G, Maviglia R, Spanu T, and Antonelli M: Effect of
aerosolized colistin as adjunctive treatment on the out-
comes of microbiologically documented ventilator-associated pneumonia. Chest. 2013;144:1768–1775.
44. Montgomery AB, Vanallance S, Abuana T, Tservistnas M,
and Davies A: A randomized double-blind placebo-controlled
dose-escalation phase 1 study of aerosolized amikacin and
Fosfomycin delivered via the PARI investigational
eFlow(R) inline nebulizer system in mechanically venti-
lated patients. J Aerosol Med Pulm Drug Deliv. 2014;27:
441–448.
61. American Thoracic S; and Infectious Diseases Society of A: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.

62. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, and Bonten MJ: Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13:665–671.

63. Kalanuria AA, Ziai W, and Mirski M: Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18:208.

64. Cuccia AD, Ashraf S, McPeck M, Samuel J, and Smaldone GC: Wet-side breath-enhanced jet nebulization: Controlling drug delivery during mechanical ventilation. Respir Care. 2020;65:1077–1089.

65. Gowda AA, Cuccia AD, and Smaldone GC: Reliability of vibrating mesh technology. Respir Care. 2017;62:65–69.

66. Ashraf S, McPeck M, Cuccia AD, and Smaldone GC: Comparison of vibrating mesh, jet, and breath-enhanced nebulizers during mechanical ventilation. Respir Care. 2020;65:1419–1426.

67. McPeck M, Ashraf S, Cuccia AD, and Smaldone GC: Factors determining continuous infusion aerosol delivery during mechanical ventilation. Respir Care. 2021;66:573–581.

68. Rottier BL, van Erp CJ, Sloyter TS, Heijerman HG, Frijlink HW, and Boer AH: Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv. 2009;22:263–269.

69. Miller DD, Amin MM, Palmer LB, Shah AR, and Smaldone GC: Aerosol delivery and modern mechanical ventilation: In vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003;168:1205–1209.

70. Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, and Feingold DS: Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975;293:471–475.

71. Falagas ME, Siempos II, Bliziotis IA, and Michalopoulos A: Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: A meta-analysis of comparative trials. Crit Care. 2006;10:R123.

72. Povoa FCC, Cardinal-Fernandez P, Maia IS, Rebotho MM, and Pinheiro BV: Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis. J Crit Care. 2018;43:240–245.

Received on March 26, 2021 in final form, November 10, 2021

Reviewed by:
Stephan Ehrmann
James Fink

Address correspondence to: Lucy B. Palmer, MD
Pulmonary, Critical Care and Sleep Division
Department of Medicine
Stony Brook University
HSC T7-040, 100 Nichols Road
Stony Brook, NY 11794-8172
USA

E-mail: lucy.b.palmer@stonybrookmedicine.edu